ACS Technologies: consolidated PAT up 178% YoY as revenue more than doubles to ₹114 Cr
PAT +177.64% YoY · revenue +136.22% · margins expanding
₹113.98 Cr
+136.22% YoY
₹6.58 Cr
+177.64% YoY
5.77%
+0.9pp YoY
₹0.76
ACS Technologies' consolidated revenue grew 136% YoY to ₹113.98 Cr (₹48.25 Cr in Q2 FY26) and 19.8% QoQ from ₹95.12 Cr in Q1 FY27, while consolidated PAT rose 178% YoY to ₹6.58 Cr (₹2.37 Cr) and 68% QoQ from ₹3.92 Cr — a broad-based scale-up with no exceptional items on either side, so the growth is read on a raw, unadjusted basis. Net profit margin expanded to 5.77% from 4.91% a year ago and 4.12% last quarter, but operating margin (EBITDA/revenue) eased slightly to 10.13% from 10.83% YoY even as it rebounded sharply from Q1's 7.94%, pointing to a cost mix (employee and other expenses) that hasn't fully kept pace with the revenue ramp even as the bottom line outgrew the topline. Standalone, the parent's own revenue grew faster at 178.7% YoY to ₹82.28 Cr (PAT +167.5% to ₹5.38 Cr) than the consolidated figure, because the two subsidiaries — Iotiq Innovations and Innovistas Innovations — added only about 69% YoY growth on their combined ₹31.70 Cr of revenue, diluting the group's growth rate; readers comparing the standalone release separately should expect the higher number there.
Q2 FY-2027 vs prior quarters
There is no analyst coverage or consensus estimate available for this sub-₹115 Cr-revenue company, so the print cannot be benchmarked against the Street, and management has issued no formal guidance or prior concall commentary on record against which to grade this quarter — both read as 'unknown' rather than a miss. The quarter coincided with a flurry of capital-structure activity: ₹20.38 Cr was raised via share warrants in H1 FY27 (lifting paid-up equity capital to ₹69.44 Cr from ₹60.74 Cr), a 49.5-lakh-share preferential allotment received BSE listing approval on October 19-23, and credit facilities were enhanced by ₹30 Cr on October 31 — all funding lined up alongside the receivables and inventory build (trade receivables up to ₹103.20 Cr from ₹75.97 Cr, inventories to ₹85.80 Cr from ₹80.43 Cr) that typically accompanies this scale of revenue growth. No management press release accompanied this filing, so there is no company framing to reconcile against the numbers beyond the board outcome letter.
The stock went into the print at ₹72.4, up 7.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters.
What the summary numbers don't show
Consolidated basic EPS ₹0.76 vs ₹0.39 YoY and ₹0.65 QoQ
W1
Whether OPM recovers back toward the ~10.8% YoY level — it dipped to 7.94% in Q1 FY27 before rebounding to 10.13% this quarter
W2
Subsidiary (Iotiq/Innovistas) combined revenue growth, currently ~69% YoY on ₹31.70 Cr — well behind standalone's 178.7% YoY pace
W3
Deployment of the ₹20.38 Cr share-warrant proceeds and the ₹30 Cr enhanced credit facility (Oct 31, 2026) against the receivables/inventory build
Figures converted from ₹ Lakhs. No exceptional items in either period. Current-quarter consolidated Net Profit/(Loss) row shows NCI as nil while the Total Comprehensive Income row attributes ₹58.82 Lakh to NCI for the same quarter — a presentation inconsistency in the filing; used the total Net Profit/(Loss) row (658.15 Lakh) as consolidated PAT, matching the convention in our prior-period DB context figures.